Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090824 | PMC |
| http://dx.doi.org/10.1002/ueg2.12690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted Therapies and Computational Approaches in the Management of Crohn's Disease.
Curr Gene Ther
August 2025
Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh, India.
Crohn's disease (CD), a chronic inflammatory disorder of the gastrointestinal tract, presents significant challenges in clinical medicine due to its multifactorial etiology and varied therapeutic responses. This review examines the diverse causes of CD, including genetic predispositions identified through genome-wide association studies (GWAS), which involve scanning the genome for single-nucleotide polymorphisms associated with CD risk, as well as environmental triggers, such as diet and alterations in the microbiome. Biomarkers, such as fecal calprotectin and Creactive protein (CRP), as well as genetic markers like NOD2 mutations, provide critical tools for diagnosis and treatment stratification.
View Article and Find Full Text PDFCombination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.
J Crohns Colitis
September 2025
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Advanced combination treatment (ACT)-the combination of two advanced agents such as biologics or small molecules-has emerged as a promising strategy in the management of inflammatory bowel disease refractory to conventional treatment, with severe extraintestinal manifestations, or with coexisting immune-mediated inflammatory diseases. ACT including complementary mechanisms of action aims to overcome the therapeutic ceiling observed with monotherapy. Its rationale is supported by preclinical and mechanistic data demonstrating synergistic immunological effects when distinct inflammatory pathways are targeted simultaneously.
View Article and Find Full Text PDFAn exploratory single-cell analysis of peripheral blood mononuclear cells from vedolizumab-treated Crohn's disease patients identifies response-associated differences among the plasmacytoid dendritic cells and classical monocytes.
Front Immunol
September 2025
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands.
Background: Vedolizumab (VDZ) is a monoclonal antibody approved for the treatment of Crohn's disease (CD). Despite its efficacy, non-response to VDZ is common in clinical practice with no clear understanding of how it manifests. Here, we performed an exploratory study characterizing the cellular repertoire of responders and non-responders to VDZ during treatment.
View Article and Find Full Text PDFFaecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR study.
J Crohns Colitis
September 2025
Department of Gastroenterology, Guy's & St Thomas' Hospital.
Background And Aims: We conducted a prospective study (FAVOUR) of patients with UC commencing vedolizumab to investigate faecal vedolizumab loss and its impact on serum levels and treatment outcomes.
Methods: FAVOUR recruited patients with moderate-to-severe UC commencing vedolizumab. Faecal vedolizumab levels (FVL) were measured at days 1, 4, 7 and at weeks 2, 6 and 14.
Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis.
Pharmaceuticals (Basel)
July 2025
Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
: Vedolizumab is a gut-selective anti-integrin monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). While clinical trials have demonstrated a favorable safety profile, real-world studies are essential for identifying rare adverse events (AEs) and evaluating post-marketing safety. This study assessed vedolizumab's safety in a real-world cohort and supported the detection of potential safety signals.
View Article and Find Full Text PDF